Current neuropharmacology

Why Treatments Targeting Gut-Brain Communication Often Fail and the Need for Personalized and Long-Term Study Designs

Updated

Abstract

The biological heterogeneity among individuals may significantly affect the outcomes of gut-centric therapies.

  • Strong preclinical evidence supports the role of the gut-brain axis in various physiological regulations.
  • Therapies such as probiotics and faecal microbiota transplants show promise in animal studies but yield inconsistent results in clinical trials.
  • Individuals with similar clinical features can exhibit substantial differences in gut barrier function and immune responses.
  • Targeting specific gut-brain pathways in diverse patient groups may reduce measurable therapeutic effects.
  • A shift toward mechanism-based endophenotyping could help identify physiologically relevant patient cohorts.
  • Incorporating biomarkers and ongoing biological sampling may enhance the prediction of treatment responses.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free